Literature DB >> 15133183

Overexpression of the erbB-2 proto-oncogene in canine osteosarcoma cell lines and tumors.

A F Flint1, L U'Ren, M E Legare, S J Withrow, W Dernell, W H Hanneman.   

Abstract

The status of the erbB-2 (human epidermal growth factor receptor 2/neu) proto-oncogene in canine osteosarcoma (OSA) has not been reported previously. In this study we used real-time reverse transcriptase polymerase chain reaction to evaluate erbB-2 expression in seven canine OSA cell lines and 10 canine OSA tissue samples. We determined erbB-2 to be significantly overexpressed in 86% (six of seven) of the cell lines and 40% (4 of 10) of the OSA tissues samples. Given the importance of erbB-2 in human breast cancer, the finding of erbB-2 overexpression in canine OSA may be important in further understanding the pathogenesis and possible therapies of OSA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15133183     DOI: 10.1354/vp.41-3-291

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  15 in total

1.  Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression.

Authors:  Melissa Paoloni; Sean Davis; Susan Lana; Stephen Withrow; Luca Sangiorgi; Piero Picci; Stephen Hewitt; Timothy Triche; Paul Meltzer; Chand Khanna
Journal:  BMC Genomics       Date:  2009-12-23       Impact factor: 3.969

2.  Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.

Authors:  Nabil Ahmed; Vita S Salsman; Eric Yvon; Chrystal U Louis; Laszlo Perlaky; Winfried S Wels; Meghan K Dishop; Eugenie E Kleinerman; Martin Pule; Cliona M Rooney; Helen E Heslop; Stephen Gottschalk
Journal:  Mol Ther       Date:  2009-06-16       Impact factor: 11.454

3.  Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells.

Authors:  Melinda Mata; Juan F Vera; Claudia Gerken; Cliona M Rooney; Tasha Miller; Catherine Pfent; Lisa L Wang; Heather M Wilson-Robles; Stephen Gottschalk
Journal:  J Immunother       Date:  2014-10       Impact factor: 4.456

4.  Immunohistochemical investigation of cell cycle and apoptosis regulators (survivin, β-catenin, p53, caspase 3) in canine appendicular osteosarcoma.

Authors:  Laura Bongiovanni; Francesca Mazzocchetti; Daniela Malatesta; Mariarita Romanucci; Andrea Ciccarelli; Paolo Buracco; Raffaella De Maria; Chiara Palmieri; Marina Martano; Emanuela Morello; Lorella Maniscalco; Leonardo Della Salda
Journal:  BMC Vet Res       Date:  2012-06-11       Impact factor: 2.741

5.  Cellular and phenotypic characterization of canine osteosarcoma cell lines.

Authors:  Marie E Legare; Jamie Bush; Amanda K Ashley; Taka Kato; William H Hanneman
Journal:  J Cancer       Date:  2011-05-04       Impact factor: 4.207

6.  Reference gene validation for gene expression normalization in canine osteosarcoma: a geNorm algorithm approach.

Authors:  Gayathri Thevi Selvarajah; Floor A S Bonestroo; Elpetra P M Timmermans Sprang; Jolle Kirpensteijn; Jan A Mol
Journal:  BMC Vet Res       Date:  2017-11-25       Impact factor: 2.741

Review 7.  Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging Therapies.

Authors:  Breann C Sommer; Deepika Dhawan; Timothy L Ratliff; Deborah W Knapp
Journal:  Bladder Cancer       Date:  2018-04-26

8.  Characterization of STAT3 activation and expression in canine and human osteosarcoma.

Authors:  Stacey L Fossey; Albert T Liao; Jennifer K McCleese; Misty D Bear; Jiayuh Lin; Pui-Kai Li; William C Kisseberth; Cheryl A London
Journal:  BMC Cancer       Date:  2009-03-10       Impact factor: 4.430

9.  Comparative analysis of the surface exposed proteome of two canine osteosarcoma cell lines and normal canine osteoblasts.

Authors:  Milan Milovancev; Ian Hilgart-Martiszus; Michael J McNamara; Cheri P Goodall; Bernard Seguin; Shay Bracha; Samanthi I Wickramasekara
Journal:  BMC Vet Res       Date:  2013-06-13       Impact factor: 2.741

10.  Coexistence of HER2, Ki67, and p53 in Osteosarcoma: A Strong Prognostic Factor.

Authors:  Keykhosro Mardanpour; Mahtab Rahbar; Sourena Mardanpour
Journal:  N Am J Med Sci       Date:  2016-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.